Targeting LARP1 Enhances Carboplatin Sensitivity and Suppresses Tumor Growth in Endometrial Cancer
This study demonstrates that LARP1 overexpression drives endometrial cancer progression and chemoresistance by upregulating E2F1 and suppressing apoptosis, while its inhibition sensitizes tumors to carboplatin and reduces growth, highlighting LARP1 as a promising therapeutic target.